References
1. Liu P, Wang L, Han D, Sun C, Xue X, Li G. Acquired long QT syndrome
in chronic kidney disease patients. Ren Fail. 2020 Nov;42(1):54–65.
2. Patanè S, Marte F, Di Bella G, Currò A, Coglitore S. QT interval
prolongation, torsade de pointes and renal disease. Vol. 130,
International journal of cardiology. Netherlands; 2008. p. e71-3.
3. Alramly M, Darawad MW, Khalil AA. Slowing the progression of chronic
kidney disease: comparison between predialysis and dialysis in Jordanian
patients. Ren Fail. 2013;35(10):1348–52.
4. Familoni OB, Alebiosu CO, Ayodele OE. Effects and outcome of
haemodialysis on QT intervals and QT dispersion in patients with chronic
kidney disease. Cardiovasc J South Africa Off J South Africa Card Soc
[and] South African Soc Card Pract. 2006;17(1):19–23.
5. Sherif KA, Abo-Salem E, Panikkath R, Nusrat M, Tuncel M. Cardiac
repolarization abnormalities among patients with various stages of
chronic kidney disease. Clin Cardiol. 2014 Jul;37(7):417–21.
6. Näppi SE, Virtanen VK, Saha HHT, Mustonen JT, Pasternack AI.
QTc dispersion increases during hemodialysis with
low-calcium dialysate. Kidney Int [Internet]. 2000 May
1;57(5):2117–22. Available from:
https://doi.org/10.1046/j.1523-1755.2000.00062.x
7. Khosoosi Niaki MR, Saravi M, Oliaee F, Akbari R, Noorkhomami S,
Bozorgi Rad SH, et al. Changes in QT interval before and after
hemodialysis. Casp J Intern Med. 2013;4(1):590–4.
8. Oktavia D, Nasution SA, Setiati S. The clinical factors’ prediction
of increased intradialytic QT dispersion on the electrocardiograms of
chronic hemodialysis patients. Saudi J kidney Dis Transplant an Off Publ
Saudi Cent Organ Transplantation, Saudi Arab. 2013 Mar;24(2):274–80.
9. Liu P, Han D, Sun X, Tan H, Wang Z, Liu C, et al. Prevalence and risk
factors of acquired long QT syndrome in hospitalized patients with
chronic kidney disease. J Investig Med Off Publ Am Fed Clin Res. 2019
Feb;67(2):289–94.
10. Gussak I, Gussak HM. Sudden cardiac death in nephrology: focus on
acquired long QT syndrome. Nephrol Dial Transplant [Internet].
2006;22(1):12–4. Available from: https://doi.org/10.1093/ndt/gfl587
11. Voroneanu L, Covic A. Arrhythmias in hemodialysis patients. J
Nephrol. 2009;22(6):716–25.
12. Bignotto LH, Kallás ME, Djouki RJT, Sassaki MM, Voss GO, Soto CL, et
al. Electrocardiographic findings in chronic hemodialysis patients. J
Bras Nefrol ’orgao Of Soc Bras e Latino-Americana Nefrol.
2012;34(3):235–42.
13. Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S,
et al. Association of QT-Prolonging Medication Use in CKD with
Electrocardiographic Manifestations. Clin J Am Soc Nephrol. 2017
Sep;12(9):1409–17.
14. Tisdale JE. Drug-induced QT interval prolongation and torsades de
pointes: Role of the pharmacist in risk assessment, prevention and
management. Can Pharm J (Ott). 2016 May;149(3):139–52.
15. The Hashemite Kingdom of Jordan Ministry of Health NDD. National
Registry of End Stage Renal Disease Annual Report [Internet]. 2008.
Available from: https://www.moh.gov.jo/
16. Khalil AA, Darawad M, Al Gamal E, Hamdan-Mansour AM, Abed MA.
Predictors of dietary and fluid non-adherence in Jordanian patients with
end-stage renal disease receiving haemodialysis: a cross-sectional
study. J Clin Nurs. 2013 Jan;22(1–2):127–36.
17. Al-Azzam SI, Abu-Dahoud EY, El-Khatib HA, Dawoud TH, Al-Husein BA.
Etiologies of chronic renal failure in Jordanian population. J Nephrol.
2007;20(3):336–9.
18. Al-Azayzih A, Gharaibeh S, Jarab AS, Mukattash TL. Prevalence of
Torsades de Pointes inducing drugs usage among elderly outpatients in
North Jordan Hospitals. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2018
Dec;26(8):1146–54.
19. Khalil AA, Abed MA, Ahmad M, Mansour AH. Under-diagnosed chronic
kidney disease in Jordanian adults: prevalence and correlates. J Ren
Care. 2018 Mar;44(1):12–8.
20. Al-Niemat SI, Aljbouri TM, Goussous LS, Efaishat RA, Salah RK.
Antibiotic Prescribing Patterns in Outpatient Emergency Clinics at Queen
Rania Al Abdullah II Children’s Hospital, Jordan, 2013. Oman Med J. 2014
Jul;29(4):250–4.
21. Otoom S, Batieha A, Hadidi H, Hasan M, Al Saudi K. Evaluation of
drug use in Jordan using WHO prescribing indicators. EMHJ - Eastern
Mediterranean Health Journal, 8 (4-5), 537-543, 2002. 2002. p. 537–43.
22. Ababneh MA, Al-Azzam SI, Ababneh R, Rababa’h AM, Demour S Al.
Antibiotic prescribing for acute respiratory infections in children in
Jordan. Int Health [Internet]. 2017;9(2):124–30. Available from:
https://doi.org/10.1093/inthealth/ihx003
23. Al-Azzam SI, Alzoubi KH, Mhaidat NM, Haddadin RD, Masadeh MM, Tumah
HN, et al. Preoperative antibiotic prophylaxis practice and guideline
adherence in Jordan: a multi-centre study in Jordanian hospitals. J
Infect Dev Ctries. 2012 Oct;6(10):715–20.
24. Zalloum N, Farha R, Awwad O, Samara N. Inappropriate prescribing of
proton pump inhibitors among patients in two Jordanian tertiary health
facilities. Trop J Pharm Res. 2016;15:1319–26.
25. Alqudah M, Al-Azzam S, Alzoubi K, Alkhatatbeh M, Rawashdeh N.
Overuse of proton pump inhibitors for stress ulcer prophylaxis in
Jordan. Int J Clin Pharmacol Ther. 2016;54.
26. Yasein N, Barghouti F, Irshaid Y, Suleiman A, Abu-Hassan D, Tawil R.
Elderly Patients in Family Practice: Polypharmacy and Inappropriate
Prescribing - Jordan. Int Med J. 2012;19.
27. AlQerem W, Jarrar Y, Alshaikh I, Madani A. The prevalence of
drug-drug interactions and polypharmacy among elderly patients in
Jordan. 2018;29.
28. Aburuz SM, Bulatova NR, Yousef A-MM, Al-Ghazawi MA, Alawwa IA,
Al-Saleh A. Comprehensive assessment of treatment related problems in
hospitalized medicine patients in Jordan. Int J Clin Pharm. 2011
Jun;33(3):501–11.
29. AbuRuz SM, Alrashdan Y, Jarab A, Jaber D, Alawwa IA. Evaluation of
the impact of pharmaceutical care service on hospitalized patients with
chronic kidney disease in Jordan. Int J Clin Pharm. 2013
Oct;35(5):780–9.
30. Hayes BD, Klein-Schwartz W, Barrueto F. Polypharmacy and the
Geriatric Patient. Clin Geriatr Med. 2007;23(2):371–90.
31. Teixeira JJV, Crozatti MTL, dos Santos CA, Romano-Lieber NS.
Potential Drug-Drug Interactions in Prescriptions to Patients over 45
Years of Age in Primary Care, Southern Brazil. PLoS One [Internet].
2012;7(10):1–6. Available from:
https://doi.org/10.1371/journal.pone.0047062
32. Patel VK, Acharya LD, Rajakannan T, Surulivelrajan M, Guddattu V,
Padmakumar R. Potential drug interactions in patients admitted to
cardiology wards of a south Indian teaching hospital. Australas Med J.
2011;4(1):9–14.
33. Assefa S, Mekonen Z. Potential Drug-Drug Interactions Among Adult
Patients Admitted to Medical Wards at a Tertiary Teaching Hospital in
Ethiopia. 2018;8:348–54.
34. Wilcock A, Charlesworth S, Twycross R, Waddington A, Worthington O,
Murtagh FEM, et al. Prescribing Non-Opioid Drugs in End-Stage Kidney
Disease. J Pain Symptom Manage [Internet]. 2017;54(5):776–87.
Available from:
http://www.sciencedirect.com/science/article/pii/S0885392417304190
35. McHugh ML. Interrater reliability: the kappa statistic. Biochem
medica. 2012;22(3):276–82.
36. Rao JNK SA. On simple adjustments to chi-square tests with sample
survey data. 1987;
37. Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz
JH, et al. Frequency of high-risk use of QT-prolonging medications.
Pharmacoepidemiol Drug Saf [Internet]. 2006;15(6):361–8. Available
from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.1155
38. Curtis LH, Østbye T, Sendersky V, Hutchison S, Allen LaPointe NM,
Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of
about 5 million outpatients. Am J Med. 2003 Feb;114(2):135–41.
39. Moreno-Gutiérrez PA, Gaviria-Mendoza A, Cañón MM, Machado-Alba JE.
High prevalence of risk factors in elderly patients using drugs
associated with acquired torsades de pointes chronically in Colombia. Br
J Clin Pharmacol. 2016 Aug;82(2):504–11.
40. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W.
Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de
Pointes in Germany. Eur Eur pacing, arrhythmias, Card Electrophysiol J
Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc
Cardiol. 2014 Jan;16(1):101–8.
41. Das B, Rawat VS, Ramasubbu SK, Kumar B. Frequency, characteristics
and nature of risk factors associated with use of QT interval prolonging
medications and related drug-drug interactions in a cohort of psychiatry
patients. Therapie. 2019 Dec;74(6):599–609.
42. Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P,
Fastbom J. Antidepressants and antipsychotics classified with torsades
de pointes arrhythmia risk and mortality in older adults - a Swedish
nationwide study. Br J Clin Pharmacol. 2016 Apr;81(4):773–83.
43. AlRuthia Y, Alkofide H, Alosaimi FD, Sales I, Alnasser A, Aldahash
A, et al. Drug-drug interactions and pharmacists’ interventions among
psychiatric patients in outpatient clinics of a teaching hospital in
Saudi Arabia. Saudi Pharm J [Internet]. 2019;27(6):798–802.
Available from:
http://www.sciencedirect.com/science/article/pii/S1319016419300738
44. Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010
Jul;2(3):326–31.
45. Shafiekhani M, Moosavi N, Firouzabadi D, Namazi S. Impact of
Clinical Pharmacist’s Interventions on Potential Drug-Drug Interactions
in the Cardiac Care Units of Two University Hospitals in Shiraz, South
of Iran. J Res Pharm Pract. 2019;8(3):143–8.
46. Sommer J, Seeling A, Rupprecht H. Adverse Drug Events in Patients
with Chronic Kidney Disease Associated with Multiple Drug Interactions
and Polypharmacy. Drugs Aging. 2020 May;37(5):359–72.
47. Curtis LH, Østbye T, Sendersky V, Hutchison S, Dans PE, Wright A, et
al. Inappropriate Prescribing for Elderly Americans in a Large
Outpatient Population. Arch Intern Med [Internet].
2004;164(15):1621–5. Available from:
https://doi.org/10.1001/archinte.164.15.1621
Figure legends